2011
DOI: 10.1007/s00439-011-0995-8
|View full text |Cite
|
Sign up to set email alerts
|

RNAi: a potential new class of therapeutic for human genetic disease

Abstract: Dominant negative genetic disorders, in which a mutant allele of a gene causes disease in the presence of a second, normal copy, have been challenging since there is no cure and treatments are only to alleviate the symptoms. Current therapies involving pharmacological and biological drugs are not suitable to target mutant genes selectively due to structural indifference of the normal variant of their targets from the disease-causing mutant ones. In instances when the target contains single nucleotide polymorph… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
68
0
1

Year Published

2012
2012
2019
2019

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 93 publications
(71 citation statements)
references
References 217 publications
1
68
0
1
Order By: Relevance
“…RNA interference strategies have been suggested for some autosomal dominant SCAs. 80 For further and up-to-date information, readers may search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions.…”
Section: Therapies Under Investigationmentioning
confidence: 99%
“…RNA interference strategies have been suggested for some autosomal dominant SCAs. 80 For further and up-to-date information, readers may search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions.…”
Section: Therapies Under Investigationmentioning
confidence: 99%
“…RNA interference (RNAi)-based systems modulate gene Prion volume 8 issue 1 expression at both transcriptional and posttranslational levels. 89 This latter method represents a very interesting strategy because it is highly specific (a desired characteristic in pharmacological drugs). 89 Such a strategy could be adopted for targets involving diseases caused by dominant gain-of-function mutations where the normal variant must be distinguished from the mutated form and where concentrations of the mutated protein in the cell must be decreased.…”
Section: Therapeutic Approaches To Preventing Aggregationmentioning
confidence: 99%
“…These techniques target a highly specific sequence present in the mRNA of a target protein, leading to decreased translation (RNAi) or degradation of the mRNA transcript (RNAi/ASO) [84][85][86]. RNAi techniques can preferentially decrease the expression of a mutant allele over the wild-type transcript, as base pair mismatches between the siRNA and target RNA inhibit their binding and subsequent degradation [86]. Furthermore, these techniques allow for great versatility in the region targeted by these nucleotides, while retaining specificity due to unique mRNA sequences in the target transcripts.…”
Section: Rnai and Antisense Oligonucleotide Therapiesmentioning
confidence: 99%
“…Furthermore, these techniques allow for great versatility in the region targeted by these nucleotides, while retaining specificity due to unique mRNA sequences in the target transcripts. This form of treatment has been used in a mouse model of prion disease, and shRNA mediated knockdown of PrP in just a subset of neurons greatly extended the length of survival compared to control mice [82] While RNAi based systems show great promise in treating several diseases [84,86], limited uptake into cells and distribution to target tissues have hindered their use in vivo, and unforeseen off-target interactions may cause adverse effects in patients. Furthermore, high levels of shRNA appear to compete with endogenous miRNA processing, and have produced harmful effects in vivo [86].…”
Section: Rnai and Antisense Oligonucleotide Therapiesmentioning
confidence: 99%
See 1 more Smart Citation